RANBAXY

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated September 17, 2009, titled "Ranbaxy in-licenses cosmetic product, Neuronox, from Medy - Tox, South Korea, for Indian market - Strengthens presence in Dermatological segment". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_PR_17092009.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated September 03, 2009, titled "Ranbaxy Launches Authorized Generic Version of Rocaltrol". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/RANBAXY_PR_03092009.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated September 01, 2009, titled "Daiichi Sankyo and Ranbaxy Leverage New Business Model with Launch of EVISTA in Romania". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/RANBAXY_Pr_01092009.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated August 24, 2009, titled "Ranbaxy receives Final Approval from USFDA to manufacture and market Glycopyrrolate Tablets". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_PR_24082009.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated August 12, 2009, titled "Ranbaxy Launches Protein Supplement - 'Revitalite' in India; Strengthens Presence in Nutritional Supplements Market". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_PR_12082009.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated August 11, 2009, titled "Ranbaxy Receives Final Approval From USFDA To Market Sumatriptan Succinate Tablets". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/RANBAXY_PR_11082009.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated August 04, 2009, titled "Ranbaxy Launches Generic Losartan in Malaysia on Day-One ". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/RANBAXY_PR_04082009.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated July 29, 2009, titled "Ranbaxy gains approval to market Ran-Ropinirole Tablets in Canada". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_PR_29072009.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated July 24, 2009, titled "Q2 FY 2009 Results; Profit After Tax Rs.6,931 MN, Global Sales At Rs.17,953 MN 14% Growth Over Previous Quarter". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/RANBAXY_pr_24072009.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated July 23, 2009, titled "Ranbaxy's non-sterile drug plant at Dewas receives GMP Compliance approval from MHLW- Japan - Approval applies to all product filings for Japan for a period of 5 years". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/RANBAXY_pr_23072009.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated July 21, 2009, titled "Ranbaxy receives Final Approval to manufacture and market RAN-SIMVASTATIN tablets in Canada". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/ranbaxy_pr_21072009.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated July 20, 2009, titled "Ranbaxy receives Final Approval to manufacture and market RAN-AMLODIPINE tablets in Canada". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_PR_20072009.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated May 24, 2009, titled "Ranbaxy and Daiichi Sankyo Announce Reconstitution of Ranbaxy Executive Leadership." A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_PR_25052009.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated May 21, 2009, titled "Ranbaxy consolidates presence in Dermatology Segment - Acquires Brands from Ochoa Laboratories Ltd.". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/ranbaxy_pr_21052009.ZIP target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated May 06, 2009, titled "Basics, Ranbaxy's subsidiary in Germany, to provide generic medicines in Germany under AOK agreement". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/RANBAXY_PR_06052009.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated May 04, 2009, titled "RANBAXY COMMENCES PHASE-III CLINICAL TRIALS FOR ITS NEW ANTI-MALARIAL MOLECULE". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy01_PR_04052009.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated May 02, 2009, titled "Ranbaxy Voluntarily Recalls Nitrofurantoin Capsules in the U.S.". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_PR_04052009.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated April 24, 2009, titled "Q1 2009 Global Sales at Rs.15,584 MN - Emerging Markets Steady Despite Adverse Economic and Monetary Conditions". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/ranbaxy_pr_24042009.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated March 31, 2009, titled "Ranbaxy to launch Daiichi Sankyo's innovative antihypertensive, Olvance, in India: First product from Daiichi Sankyo's portfolio to be introduced through Ranbaxy". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_PR_31032009.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated March 30, 2009, titled "Ranbaxy Gains Final Approval from USFDA for Topirimate Tablets- Fourth ANDA from Ranbaxy to be approved in the last two Months". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_PR_30032009.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated March 25, 2009, titled "TGA- Australia Grants Approval for OZIDAL Risperidone Tablets". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_PR_25032009.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated March 23, 2009, titled "Ranbaxy's Paonta Sahib plant receives MHRA, UK and TGA, Australia Approvals for GMP Compliance - MHRA approval will also apply to all product filings for the EU". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_PR_23032009.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated March 09, 2009, titled "Ranbaxy gains Final Approval from USFDA for Ramipril Capsules; Third ANDA from Ranbaxy to be approved in the last two months". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_PR_09032009.ZIP target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated March 06, 2009, titled "Ranbaxy gets TGA-Australia approval for SEBIFIN Terbinafine Tablets". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/ranbaxy_PR_06032009.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated March 05, 2009, titled "Ranbaxy secures USFDA approval for Quinapril+HCTZ Tablets". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_PR_05032009.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated January 22, 2009, titled "FY 2008 Global Sales at Rs.72,507 MN (+8%); Q4 2008 Global Sales at Rs.19,096 MN (+6%) - Emerging Markets Deliver Consistent Growth of 9% During the year; Developed Markets Grow 7% - Landmark Alliance with Daiichi Sankyo Completed; Company Receives Rs.35849 MN; Positioned for Stronger Growth". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated January 09, 2009, titled "Ranbaxy's Drug Discovery Team achieves significant landmark in GSK Research Collaboration; Starts Phase I Clinical Studies for Respiratory Inflammation Program". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_PR_09012009.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated December 19, 2008, titled "Ranbaxy Reconstitutes Board of Directors following Strategic Alliance with Japan's Daiichi Sankyo - Ranbaxy CEO and Managing Director Malvinder Mohan Singh Takes Additional Role as Chairman of the Ranbaxy Board". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_PR_19122008.ZIP target=NEW> For more details cl

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated December 03, 2008, titled "Ranbaxy to market USFDA approved drug, for treatment of brain tumor, in India- Signs exclusive Licensing agreement with BioPro Pharmaceutical, Inc., USA". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_PR_03122008.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated November 07, 2008, titled "Ranbaxy and Daiichi Sankyo Successfully Complete Landmark Deal". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_PR_07112008.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding the press release dated October 31, 2008, titled "Q3 2008 Global Sales at Rs.18,884 MN (+14%); Emerging Markets Deliver Strong Growth of 20%; Developed Markets Grow by 9%". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). <a href=/content/corporate/Ranbaxy_PR_31102008.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding the press release dated October 20, 2008, titled "Ranbaxy and Daiichi Sankyo Move Forward Toward The Completion of the Landmark Deal". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/ranbaxylab_PR_20102008.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated October 16, 2008, titled "Ranbaxy achieves a significant landmark in Anti-Malarial Research; Obtains approval from DCGI to conduct Phase III Clinical Trial for its anti-malarial combination drug". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_PR_17102008.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated October 13, 2008, titled "Ranbaxy achieves another significant Milestone in GSK Research Collaboration; Submits IND application to DCGI for Respiratory Inflammation Candidate". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_PR_13102008.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated August 01, 2008, titled "Ranbaxy's ARV Drug, Abacavir 300MG Tablets ,Included in WHO's Pre-Qualification List; Company Now Has a Total of 18 ARVS in the WHO Program; Ranbaxy Committed to Support the Global Fight Against HIV/AIDS". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_Pr_01082008.zip target=NEW> For more details click her

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated July 29, 2008, titled "Q2 2008 Global Sales at USD 440 Mn (Rs 18,296 Mn), + 11%; Operating Profit after Tax steady at USD 39 Mn (Rs 1,608 Mn); Company brings certainty by settling litigation with Pfizer on worlds largest selling drug Atorvastatin, with Annual Sales of USD 12.7 Bn; Landmark deal with Daiichi Sankyo to benefit Ranbaxy in charting a higher trajectory of growth". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and o

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated July 28, 2008, titled "Ranbaxy launches Omeprazole 40 MG Capsules". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_PR_28072008.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated July 23, 2008, titled "Ranbaxy Launches Generic Amlodipine Tablets on Day-1 in Japan - First independently developed generic product outside of Japan to have received marketing approvals of MHLW (Japan)". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/ranbaxy_pr_23072008.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated July 22, 2008, titled "Ranbaxy Wins UK SFO Case". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_Pr_22072008.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated July 17, 2008, titled "Daiichi Sankyo and Ranbaxy confirm Deal is Binding and Final Allay market rumour and speculation". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/RAN_PR_17072008.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated June 25, 2008, titled "Ranbaxy Gains Tentative Approval to Manufacture and Market Valganciclovir Hydrochloride Tablets; "First-to-File" Status Will Provide 180-Day Marketing Exclusivity Upon Final Approval". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_PR_25062008.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated June 18, 2008, titled "Ranbaxy and Pfizer Settle Lipitor Litigation Worldwide; Ranbaxy will Market Generic Atorvastatin in the U.S. with 180 Days Exclusivity from Nov. 30, 2011; Agreement Also Resolves Caduet, Accupril Litigation in the US". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/ranbaxy_pr_18062008.zip target=NEW> For more details c

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated June 11, 2008, titled "Ranbaxy to bring in Daiichi Sankyo Company Limited as Majority Partner Strategic Combination creates Innovator and Generic Pharma Powerhouse". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_PR_11062008.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated May 28, 2008, titled "Full Federal Court affirms the Australian Federal Court's Decision in Favor of Ranbaxy on Pfizer's Atorvastatin Patent on Appeal- Overall ruling mixed as court also upholds decision on another Pfizer patent". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_PR_28052008.zip target=NEW> For more details click here.<

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated May 21, 2008, titled "Ranbaxy Strengthens Presence In Middle East Region - Launches Business Operation in Yemen". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_PR_21052008.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated May 12, 2008, titled "Ranbaxy & Merck Sign Anti-Infective Drug Discovery and Development Agreement". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_PR_12052008.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated April 25, 2008, titled "Ranbaxy Receives Final US FDA Approval To Manufacture And Market Certirizine Hydrochloride Oral Solution". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_PR_25042008.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated April 22, 2008, titled "Q1 2008 Global Sales at USD 409 Mn (Rs 16,231 Mn), +15%; Net Profit at USD 39 Mn (Rs 1,530 Mn), +19%; Company expects significant upside from Nexium (Esomeprazole) settlement, 2nd largest selling drug in US (Sales - $5.5 Bn)". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/RanbaxyLTD_PR_22042008.zip target=NEW> For mo

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated April 22, 2008, titled "Ranbaxy and Orchid announces Strategic Business Alliance - To leverage respective strengths for mutually beneficial business growth". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_PR_22042008.zip target=NEW> For more details click here.</a>

Ranbaxy Laboratories Ltd has informed the Exchange regarding a press release dated April 15, 2008, titled "Ranbaxy and Astrazeneca reach Agreement in Esomeprazole Patent Litigation; Companies also sign Manufacturing and Distribution Agreements". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Ranbaxy_PR_15042008.zip target=NEW> For more details click here.</a>